Statins and the primary prevention of cardiovascular events

被引：27

作者：

Clearfield M. ^{[1
]}

机构：

[1] University of North Texas Health Science Center, Fort Worth, TX 76107

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 5期

关键词：

Metabolic Syndrome; Statin; Pravastatin; Lovastatin; Myocardial Infarc;

D O I：

10.1007/s11883-006-0036-6

中图分类号：

学科分类号：

摘要：

Cardiovascular disease remains the leading cause of death in both men and women in the United States. Treating elevated low-density lipoprotein (LDL) cholesterol has been shown to be very effective in reducing the rate of coronary heart disease (CHD) in primary prevention trials; however, the data are not as robust for treating individuals categorized at either lower risk for CHD or with below-average LDL cholesterol levels. The next frontier for investigation will include strategies to determine who in these lower risk categories should be treated with statins. The growing epidemics of obesity, diabetes, and metabolic syndrome also loom as major problems that need to be incorporated into any strategy that focuses on the prevention of cardiovascular disease. In individuals with multiple cardiovascular risk factors, combination therapies tailored to address each individual's risk profile need to be considered to best decrease the likelihood of their first coronary event. Copyright © 2006 by Current Science Inc.

引用

页码：390 / 396

页数：6

共 37 条

[1]

The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, (1996)

[2]

Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)

[3]

Grundy S.M., Cleeman J.I., Bairey C.N., Et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, pp. 227-229, (2004)

[4]

Shepherd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, pp. 1301-1307, (1995)

[5]

Downs J.R., Clearfield M., Weis S., Et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 279, pp. 1615-1622, (1998)

[6]

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: A randomized placebo controlled trial, Lancet, 360, pp. 7-22, (2002)

[7]

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized placebo-controlled trial, Lancet, 360, pp. 1623-1630, (2002)

[8]

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care, JAMA, 288, pp. 2998-3007, (2002)

[9]

Sever P.S., Dalhof B., Poulter N.R., Et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial, Lancet, 361, pp. 1149-1158, (2003)

[10]

Colhoun H.M., Betteridge D.J., Durrington P.N., Et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): A multicentre randomized placebo-controlled trial, Lancet, 364, pp. 685-696, (2004)

← 1 2 3 4 →